Leerink Partners Remains Sidelined on Agios Pharma (AGIO) - PT to $56

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. COF
10. GOOGL

Go back to Leerink Partners Remains Sidelined on Agios Pharma (AGIO) - PT to $56

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

February 18, 2016 7:01 AM EST

- First Data from Phase 2 DRIVE PK Study for AG-348 in PK Deficiency and Phase 1 Healthy Volunteer Study for AG-519 to be Submitted for Presentation at EHA -

- Late-stage AG-221 and AG-120 IDH Program in AML on Track with 125-Patient Expansion Cohorts Enrolling and Multiple Frontline Trials Ongoing and Planned -     

- First Data from AG-120 Dose Expansion Cohort in Low Grade Glioma Expected in the Second Half of 2016 -

CAMBRIDGE, Mass., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:... More